Description
Introduction to Blincyto 38.5mcg Injection
Blincyto 38.5mcg Injection contains blinatumomab and is manufactured by Amgen Inc. It is a prescription immunotherapy medicine used to treat certain types of B-cell precursor acute lymphoblastic leukaemia (ALL).
Blincyto may be used in adults and children with relapsed or refractory B-cell precursor ALL. It can also be used for patients with B-cell precursor ALL who are in complete remission but have minimal residual disease (MRD). In adults with newly diagnosed Philadelphia chromosome-negative B-cell precursor ALL, Blincyto may be used together with chemotherapy.
Blinatumomab belongs to a type of immunotherapy called a bispecific T-cell engager (BiTE). It connects cancer cells carrying the CD19 protein with immune cells called T-cells through CD3. This helps the body’s immune system recognise and destroy the cancer cells.
Blincyto is given as a continuous intravenous infusion under close medical supervision because it can cause serious reactions during treatment.
Blincyto 38.5 mcg Injection (Blinatumomab) is a prescription immunotherapy used to treat specific types of B-cell precursor acute lymphoblastic leukaemia (ALL). The Blincyto generic name is blinatumomab, which helps the immune system target cancer cells. Understanding blinatumomab uses can help patients learn about this specialised treatment. For the latest Blincyto injection price, product availability, and prescription requirements, visit YourMediKart. Blincyto must be administered under specialist medical supervision.
Uses of Blincyto 38.5mcg Injection
Blincyto 38.5mcg Injection may be used for:
- Relapsed or refractory B-cell precursor ALL in adults and children.
- B-cell precursor ALL in complete remission with minimal residual disease (MRD) in adults and children.
- Newly diagnosed Philadelphia chromosome-negative B-cell precursor ALL in adults, when used in combination with chemotherapy.
The exact treatment plan depends on the patient’s age, condition, test results, and response to treatment.
Storage
- Store Blincyto in a refrigerator at 2°C to 8°C.
- Do not freeze the vial or prepared infusion bag.
- Keep the medicine in its original carton to protect it from light.
- Prepared infusion bags should be stored according to the healthcare professional’s instructions and approved product information.
- Keep the medicine out of the reach of children.
Safety Advice
- Discover product information and availability for blinatumomab price in india through YourMediKart. Customers comparing blincyto price in india can contact the supplier for updated pricing and product specifications.
- If you are searching for blinatumomab prix, verify the applicable market, currency, and exact formulation. Learn more about blincyto 38.5 mcg price and confirm current availability with a reliable supplier.
- Customers researching blincyto cena can review the product listing for further information. For details about blincyto injection price or blincyto injection price in india, contact YourMediKart to confirm current costs and supply requirements.
- Explore blinatumomab price information and discuss treatment-related costs with your healthcare provider. If you are comparing blincyto 38.5 mcg price in india, verify the product presentation and prescribed treatment plan.
- Customers searching for blinatumomab prezzo should confirm the relevant pricing market and product specifications. Blincyto contains blinatumomab, a prescription immunotherapy used for certain forms of acute lymphoblastic leukemia.
- Treatment requires specialist supervision and monitoring for serious adverse reactions. Consult your oncologist for guidance about treatment suitability and administration.
Pregnancy
Consult Your Doctor
Tell your doctor if you are pregnant, planning to become pregnant, or could become pregnant. Blinatumomab may cause harm to an unborn baby. Women who can become pregnant should use effective contraception during treatment and for at least 48 hours after the last dose, as advised by their doctor.
Breastfeeding
Consult Your Doctor
Breastfeeding is generally not recommended during Blincyto treatment and for at least 48 hours after the last infusion. Talk to your doctor before breastfeeding.
Lungs
Consult Your Doctor
Blincyto can cause serious infusion-related reactions that may affect breathing. Contact your doctor immediately if you experience shortness of breath, cough, wheezing, chest tightness, or difficulty breathing during or after treatment.
Liver
Consult Your Doctor
Blincyto may cause an increase in liver enzymes. Your doctor may perform blood tests to check your liver function before and during treatment.
Alcohol
Consult Your Doctor
Talk to your doctor about alcohol consumption during Blincyto treatment. Alcohol may worsen symptoms such as tiredness or dizziness and may not be suitable during treatment.
Driving
Consult Your Doctor
Blincyto may cause neurological side effects such as dizziness, confusion, problems with coordination, or seizures. Avoid driving or operating machinery if you experience these symptoms and follow your doctor’s advice about when it is safe to drive.




Reviews
There are no reviews yet.